Strengthen your portfolio by making more informed decisions and prepare for the impact of new research discoveries.
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREYour new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MORE"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESGenome editing technologies have brought major breakthroughs in science and medicine leading to the invention of clustered regularly interspaced short palindromic repeats (CRISPR) as a gene editing tool to edit DNA. CRISPRs are repeating DNA sequences in the genome of prokaryotes, including bacteria, and were first discovered in E. coli in 1987. In the early 2000s, the role of the CRISPR and CRISPR-associated sequence (CAS) protein systems was identified as an adaptive immune response in bacteria against invading phage DNA (double-stranded DNA viruses). Later in 2012, the CRISPR-CAS9 system was adopted as a gene-editing tool for selectively editing the human genome. A Nobel Prize was awarded to the researchers who discovered the CRISPR-CAS9 genetic scissors in 2020. On 16 November 2023, the UK MHRA's approval of Vertex Pharmaceuticals and CRISPR Therapeutics' exagamglogene autotemcel (CASGEVY) marked the first time that marketing authorization has been granted to a CRISPR gene editing therapy.
This article provides an update on current approved CRISPR and other gene editing therapies and outlines the latest development activities including ongoing clinical trials of key experimental therapeutics with data sourced from IQVIA Pipeline Link and IQVIA Trial Link.
Stay informed about the latest advancements in CRISPR gene editing therapies and other genome editing systems, including authorized treatments and ongoing clinical trials. Download the article now to gain strategic insights and stay ahead in the rapidly evolving field of pharmaceutical innovation!
Strengthen your portfolio by making more informed decisions and prepare for the impact of new research discoveries.
IQVIA Analytics Link Ecosystem establishes deep connections across our key data assets.